Ardent Health Partners/$ARDT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ardent Health Partners
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S and operating in eight growing mid-sized urban markets across six states Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas. The main focus on people and investments in services and technologies.
- Ticker
- $ARDT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 22,350
- Headquarters
- Brentwood, United States
- Website
- www.ardenthealth.com
ARDT Metrics
BasicAdvanced
$1.7B
22.28
$0.55
0.70
-
Price and volume
Market cap
$1.7B
Beta
0.7
52-week high
$15.09
52-week low
$7.71
Average daily volume
458K
Financial strength
Current ratio
2.105
Quick ratio
1.455
Long term debt to equity
1.285
Total debt to equity
1.302
Interest coverage (TTM)
5.05%
Profitability
EBITDA (TTM)
422.417
Gross margin (TTM)
58.38%
Net profit margin (TTM)
1.22%
Operating margin (TTM)
4.03%
Effective tax rate (TTM)
18.91%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
3.13%
Return on equity (TTM)
9.96%
Valuation
Price to earnings (TTM)
22.278
Price to revenue (TTM)
0.271
Price to book
1.29
Price to tangible book (TTM)
4.55
Price to free cash flow (TTM)
5.707
Free cash flow yield (TTM)
17.52%
Free cash flow per share (TTM)
2.155
Growth
Revenue change (TTM)
3.34%
Earnings per share change (TTM)
-69.60%
What the Analysts think about ARDT
Analyst ratings (Buy, Hold, Sell) for Ardent Health Partners stock.
Analyst projections of the future price of Ardent Health Partners stock.
Bulls say / Bears say
Adjusted admissions grew 2.5% year on year in Q2, and Ardent is expanding specialty services in East Texas through its UT Tyler partnership. That could help it attract more patients and deepen its presence in its existing markets. (Ardent Health, Ardent Health)
Management raised its 2026 IMPACT savings target to at least $70 million from $55 million, citing operational changes and lower contract labour. If delivered, those savings could help protect margins as volumes remain uneven. (Ardent Health)
Operating cash flow rose 67% year on year to $197 million in Q2, while net leverage was 0.8 times and lease-adjusted net leverage was 2.6 times. That cash generation and balance-sheet capacity give Ardent room to fund investment and manage operating pressure. (U.S. Securities and Exchange Commission)
Q2 adjusted EBITDA fell 32.3% year on year to $115 million, and net income attributable to Ardent dropped to $17 million from $73 million. Total surgeries also declined 2.9%, including a 7.5% fall in inpatient surgeries. (Ardent Health)
Changes to Medicaid funding and eligibility rules, limits on supplemental-payment programmes and the expiry of enhanced exchange subsidies could weaken reimbursement or reduce insured patient volumes. Ardent says these policy changes may adversely affect its results. (U.S. Securities and Exchange Commission)
Ardent cut its 2026 net-income guidance to $110–163 million from $129–183 million and its diluted EPS range to $0.78–1.15 from $0.90–1.27. Management also said revenue was now biased towards the lower end of its unchanged range, reflecting weaker volumes. (Ardent Health)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
ARDT Financial Performance
Revenues and expenses
ARDT Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARDT News
AllArticlesVideos
Funds containing ARDT
Fund name | Fund size | $ARDT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.